Absci Corp. (ABSI) highlighted on-plan clinical execution and a long funding runway during its Q3 earnings call, contrasting management’s optimism with the absence of human efficacy data, higher expenses, lower cash versus the comparison figure, and an undefined endometriosis data timeline.
The randomized, placebo-controlled HEDLINE trial of ABS-201 in pattern hair loss continues to enroll and progress as planned, according to TipRanks. December 2026 is when Absci anticipates sharing interim 13-week proof-of-concept findings, which will be succeeded by the complete 26-week results early in 2027.
Management reported that emerging safety, pharmacokinetic, and immunogenicity findings remain encouraging. According to blinded aggregate interim findings, ABS-201 proved to be well tolerated and displayed a positive safety profile, notwithstanding the fact that human effectiveness has not yet been proven.
A dosing schedule of two or three injections across a six-month span was backed by interim pharmacokinetic findings derived from all four single-ascending-dose cohorts. Bearing an estimated half-life spanning roughly 60 to 65 days, administration of ABS-201 might conceivably occur every eight to 12 weeks.
Absci said it has completed enrollment in the highest-dose HEDLINE cohort. All participants given 300 milligrams, a majority of the 600-milligram group, and potentially an initial glimpse at the 1,200-milligram cohort are anticipated to be featured in the 13-week data disclosure. Meanwhile, enrollment has started in two exploratory female pattern hair loss cohorts testing 300-milligram and 1,200-milligram doses in open-label studies with no placebo arm.
Male pattern hair loss metrics regarding target-area hair count, target-area hair width, and total hair count will be part of the scheduled interim evaluation. Total hair count is being tracked by Absci because the action of its prolactin receptor pathway has the potential to impact both resting and active follicles.
Management described current pattern hair loss treatments as offering mixed efficacy, inconvenient administration, and other trade-offs. Market research involving consumers and doctors indicated that achieving a 26-week gain of 30 to 35 hairs per square centimeter in target-area hair count—roughly comparable with high-dose oral minoxidil—could establish a substantial commercial market. Absci estimates a U.S. total addressable market of about $25 billion.
Pending regulatory approval and finalization of the study protocol, Absci intends to launch the worldwide, multicenter STORILINE Phase 2 study for endometriosis in the middle of 2027. Approximately 150 participants across a minimum of 10 nations are anticipated to take part in the double-blind, placebo-controlled trial to gauge decreases in non-menstrual pelvic pain and dysmenorrhea.
Management highlighted that endometriosis may affect up to 10% of women worldwide, including an estimated 9 million women in the United States, with potential endometriosis peak sales above $4 billion if development succeeds.
The company is also exploring additional indications for its prolactin receptor antibodies and is developing ABS-202 for new uses, alongside a broader early-stage pipeline in metabolism, healthy aging, and other areas.
Related reading